Corporate Member Update: Merck- Keytruda® FDA Update
Corporate Member Update: Merck- Keytruda® FDA Update
KEYTRUDA®
August, 2021
Merck would like to share that the FDA has approved KEYTRUDA® (pembrolizumab) Injection 100mg for the treatment of patients with locally advanced sqaumous cell carcinoma (cSCC) that is not curable by rsurgery or radiation.
For more information, please review the complete press release here!
